Botox Intervention Improves Facial Asymmetry After Nerve Damage
By Elana Gotkine HealthDay Reporter
TUESDAY, March 18, 2025 -- For patients with severe oral commissure droop from facial nerve damage undergoing surgery, botulinum toxin type A (BoNT-A) treatment helps to alleviate muscle hyperactivity, leading to improvement in facial asymmetry, according to a study published in the March issue of Plastic and Reconstructive Surgery.
Hao Ma, M.D., from Shanghai Ninth People's Hospital, and colleagues examined the impact of BoNT-A treatment on the unaffected side in 38 patients with severe oral commissure droop from facial nerve damage with respect to facial symmetry and brain connectivity. Participants were divided into two groups: those who did and did not receive BoNT-A injections on the unaffected side (20 and 18 patients, respectively).
The researchers found that BoNT-A treatment improved facial symmetry and induced significant modifications in brain functional network connectivity. The modifications extended beyond the sensorimotor network, involving high-level cognitive processes. There was a significant correlation between functional network connectivity and the degree of asymmetry.
"BoNT-A treatment appears to promote significant modifications in functional brain network connectivity, thereby sustaining the positive effects of BoNT-A," the authors write. "Our findings imply that the facial asymmetry is linked to the characteristics of large-scale functional networks."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Read this next
Socioeconomic Deprivation Tied to Neurodegeneration in Combat Athletes
THURSDAY, Aug. 14, 2025 -- Athletes experiencing early-life socioeconomic disadvantage may have an increased risk for neurodegeneration from exposure to repetitive head injury...
ADHD Drug Treatment Linked to Reduced Rate of Adverse Outcomes
THURSDAY, Aug. 14, 2025 -- Attention-deficit/hyperactivity disorder (ADHD) drug treatment is associated with reduced rates of adverse outcome events, including suicidality...
2009 to 2023 Saw Increase in Use of Technology, Glycemic Control in Type 1 Diabetes
THURSDAY, Aug. 14, 2025 -- From 2009 to 2023, there was an increase in use of diabetes technology and in glycemic control among youths and adults with type 1 diabetes (T1D)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.